GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (OTCPK:BMNDF) » Definitions » Short-Term Debt

Biomind Labs (Biomind Labs) Short-Term Debt : $0.00 Mil (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs Short-Term Debt?

Biomind Labs's Short-Term Debt for the quarter that ended in Sep. 2023 was $0.00 Mil.


Biomind Labs Short-Term Debt Historical Data

The historical data trend for Biomind Labs's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs Short-Term Debt Chart

Biomind Labs Annual Data
Trend Dec21 Dec22
Short-Term Debt
- -

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Biomind Labs Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Biomind Labs Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Biomind Labs's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomind Labs (Biomind Labs) Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs (Biomind Labs) Headlines

No Headlines